Standout Papers

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis 2022 2026 2023 2024894
  1. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (2022)
    Steven R. Ytterberg, Deepak L. Bhatt et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 65 standout
Sub-graph 1 of 17

Citing Papers

Tailoring traditional Chinese medicine in cancer therapy
2025 Standout
Live zoster vaccination and cardiovascular outcomes: a nationwide, South Korean study
2025 Standout
17 intermediate papers

Works of Andrea Shapiro being referenced

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
2022 Standout
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
2021
and 2 more

Author Peers

Author Last Decade Papers Cites
Andrea Shapiro 757 276 279 12 1.2k
Jose L. Rivas 805 298 284 26 1.3k
Rebecca Germino 603 227 321 22 1.1k
Ryan DeMasi 723 376 225 30 1.0k
S Brown 338 185 376 14 1.2k
Jennifer Hodge 419 221 378 14 1.1k
M J Cuadrado 868 233 415 21 1.5k
Heikki Isomäki 559 184 191 15 1.1k
Birgitta Benda 1177 654 407 21 1.7k
Tracy Cardillo 536 250 213 12 1.0k
Christine E. Codding 601 266 498 9 1.1k

All Works

Loading papers...

Rankless by CCL
2026